The Wealth of Wealthholders.

Colchicine for secondary prevention in established ASCVD: a systematic review and meta-analysis.

The role of inflammation in longitudinal renal function decline and incident chronic kidney disease: the multi-ethnic study of atherosclerosis.

From residual risk to real risk: why implementation fails when we misunderstand the problem.

MASLD as a systemic metabolic disease: expanding the scope of cardiovascular-kidney-metabolic (CKM) syndrome.

Rethinking "Very High-Risk" ASCVD: Most Patients Qualify, Few Are Distinct?

CAC Screening for Elevated Lipoprotein(a): Clarifying ASCVD Risk Without Losing Sight of Lifetime Exposure.

2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.

2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.

Circulating Ketone Bodies and Incident Cardiovascular Outcomes and Mortality: Insights From the UK Biobank.